Inicio Zine News United Health Products Announces Completion of Human Trial Study

United Health Products Announces Completion of Human Trial Study


HENDERSON, Nev., Aug. 28, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,857,874 Oct 2015), for the healthcare and wound care sectors, today announces that the last patient has completed their follow up patient study visit in the HemoStyp Human Clinical Trial. This trial was conducted on 236 WIRB (Western Institutional Review Board) approved and consented patients. Surgeries consisted of Level 1 and Level 2 bleeds on the Lewis bleeding scale for abdominal, cardiovascular, thoracic and vascular surgeries. The patient study follow up occurs 21-40 days after the respective surgery. This is done to confirm there are no post-operative complications or related product issues. The study is a randomized trial with safety and efficacy endpoints for FDA (Food and Drug Administration) PMA Class III submission. All clinical trial post-operative follow ups have been completed and data analysis and PMA submission to the FDA will occur imminently.